Pharmaceutical compositions for the treatment and prevention of triple-negative breast cancer

By blocking T-type calcium channels and inhibiting STAT3 signaling with a compound of chemical formula 1, the treatment challenge of triple-negative breast cancer has been solved, achieving significant anti-cancer effects and preventive potential.

CN123124970APending Publication Date: 2026-11-17ONCOZEN CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202480082672.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-12-28
Filing Date
2024-12-16
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing treatments are ineffective for triple-negative breast cancer, with high recurrence rates and a lack of effective targeted therapies, resulting in poor prognosis.

Method used

Using compounds of Formula 1 as dual-target anticancer agents, these agents regulate CaMKII protein activation and induce apoptosis by blocking T-type calcium channels and inhibiting STAT3 signaling. They are prepared into pharmaceutically acceptable salt, hydrate, solvate, prodrug, and polymorphic isomer forms for the treatment and prevention of triple-negative breast cancer.

Benefits of technology

The compound of chemical formula 1 significantly inhibited the growth of triple-negative breast cancer cells in vitro and in vivo, induced apoptosis, and showed excellent anti-cancer effects. It also inhibited tumor growth and improved patient survival in mouse models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123124970A_ABST
    Figure CN123124970A_ABST
Patent Text Reader

Abstract

This invention relates to a pharmaceutical composition comprising a compound of Formula 1 for the treatment and prevention of triple-negative breast cancer. The compound of Formula 1 of this invention can exist as a pharmaceutically acceptable salt, hydrate, solvate, inclusion complex, prodrug, or polymorph isomer. The compound of Formula 1 of this invention simultaneously possesses a mechanism of blocking calcium overexpression in triple-negative breast cancer cells and essential for cancer cell growth, and a mechanism of inhibiting STAT3 as a target protein. Furthermore, this invention demonstrates that the compound of Formula 1 inhibits tumor growth in a xenograft mouse model of induced triple-negative breast cancer and exhibits antitumor activity in mouse tumor tissues via apoptosis. Formula 1:
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a pharmaceutical composition for the treatment and prevention of triple-negative breast cancer, comprising a compound of the following chemical formula 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0002] Chemical Formula 1:

[0003] Background Technology

[0004] Tumors that occur in epithelial tissues, including glandular tissues, are called adenocarcinomas. Adenocarcinomas can occur in various organs of the human body that contain epithelial tissues. The main sites where adenocarcinomas occur include the large intestine, lungs, prostate, ureters, vagina and esophagus, breast, stomach, and pancreas.

[0005] Unlike benign tumors that remain within the breast, breast cancer refers to all malignant tumors that can spread beyond the breast and endanger life. Breast cancer is a fatal disease caused by the continuous growth of abnormal tissue within the breast or its spread to other organs. Because the breast contains various cell types, any of which can become cancerous, there are many types of breast cancer. However, since most breast cancers originate from the cells of the mammary ducts and lobules (especially ductal cells), breast cancer generally refers to cancer arising from the epithelial cells of the mammary ducts and lobules (cells covering the surface of the body or the internal surface of internal organs). Breast cancer arising from the mammary ducts and lobules can be classified into invasive breast cancer and non-invasive breast cancer based on the degree of cancer cell infiltration (invasion of adjacent cells or tissues).

[0006] Triple-negative breast cancer (ER-negative PR-negative HER2 / neu-negative breast cancer), a type of invasive breast cancer, differs from most breast cancer types. It is a type of breast cancer that lacks three hormone receptors that help the cancer grow and spread: the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2). Because these receptors are not expressed, it is a type of breast cancer that responds poorly to anti-hormonal or targeted therapies and has a poor prognosis.

[0007] Triple-negative breast cancer accounts for approximately 15% of all breast cancer cases. It is a type of breast cancer that is positive for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Unlike other types of breast cancer that occur after the age of 40, triple-negative breast cancer is known to be more common in young women in their 20s and 30s or older women carrying the breast cancer gene 1 (BRCA1) mutation. Triple-negative breast cancer is extremely aggressive among breast cancer types, and therefore progresses very rapidly. 50% of patients diagnosed at an early stage relapse within 1-2 years. If diagnosed at stage 3-4, the 5-year survival rate is low, at only 30%, and it often metastasizes to the brain (30%) or lungs (40%), thus it is known to have a poor prognosis.

[0008] Treatment for triple-negative breast cancer typically involves surgical removal of the tumor, followed by radiation therapy or anticancer drugs to prevent recurrence. However, because it does not express estrogen and progesterone receptors, hormone therapy is ineffective, and it also does not express the HER2 receptor, thus failing to respond to targeted therapy. Cytotoxic chemotherapy remains the primary treatment method. Currently, although doxorubicin, docetaxel, and paclitaxel are used for triple-negative breast cancer, the recurrence rate is high. If the recurrence is metastatic triple-negative breast cancer, the progression-free survival (the period from cancer treatment to recurrence) is short, averaging less than 6 months, and overall survival is limited to about 1 year.

[0009] In recent years, new therapeutic agents for triple-negative breast cancer have been developed, including the PARP inhibitor leprazolam, the immunotherapy Keytruda, and Topavir, an antibody-drug conjugate (ADC) targeting the Trop-2 protein.

[0010] The compound of chemical formula 1 used in this invention is the compound disclosed in WO 2014 / 021591 A2 and WO 2015 / 178608 A2, which has anticancer activity through T-type calcium channel antagonism.

[0011] As is well known, calcium plays a vital role as an intracellular signaling molecule and participates in cell growth by regulating various cellular functions (Reference: Berridge, MJ, et al., Nat. Rev. Mol. Cell Biol. 2003, 4, 517-529). For example, during cell mitosis, calcium signaling is required for the transition from the G1 phase to the S phase of the cell cycle. Depletion of intracellular calcium can cause cell cycle arrest at an intermediate stage between the G0 / G1 phase and the S phase (Reference: Clapham, DE Cell 1995, 80, 259-268). The regulation of intracellular calcium levels is mediated by T-type calcium channels, based on recent reports that T-type calcium channel blockers inhibit cell differentiation (References: McCalmont, WF et al., Bioorg. Med. Chem. Lett. 2004, 14, 3691-3695; McCalmont, WF et al., Bioorg. Med. Chem. 2005, 13, 3821-3839).

[0012] As is well known, the regulation of T-type calcium channels can be applied to various diseases, such as brain diseases like epilepsy and hypertension, heart diseases like angina, pain diseases like chronic pain and neuropathic pain, or as an anticancer agent. T-type calcium channels are composed of three subtypes: a1G (Cav3.1), a1H (Cav3.2), and a1I (Cav3.3). It is known that by regulating the amount of calcium entering the cell, the activation of CaMKII protein is regulated, thereby regulating the growth and metastasis of cancer cells.

[0013] On the other hand, although still controversial, L-type calcium channel blockers, as treatments for hypertension, have the potential to induce cancer in older adults, unlike T-type calcium channel blockers. For example, some studies have reported promoting the growth of existing cancer cells in the body by inhibiting cell death (Reference: La Vecchia, C. et al., Eur. J. Cancer 2003, 39, 7-8). Therefore, selective T-type calcium channel blockers could become novel drugs for treating cancer cells with abnormal cell cycles.

[0014] WO 2008 / 136631 A1 discloses a 3,4-dihydroquinazoline derivative of the following chemical formula A, which can be used as a novel chemoanticancer drug that can treat hyperproliferative diseases such as cancer by blocking T-type calcium channels, which have a different mechanism of action than existing drugs.

[0015] Chemical formula A:

[0016]

[0017] WO 2014 / 021591 A2 discloses a hydrogenated quinazoline derivative of the following chemical formula B as an antagonist of T-type calcium channels for the treatment and prevention of disorders and diseases related to the function of T-type calcium channels.

[0018] Chemical formula B:

[0019]

[0020] The compound represented by the chemical formula B is disclosed to inhibit the flow of calcium through calcium channels and to inhibit the growth of various types of cancer cells. Therefore, it can be used as a calcium channel blocker and an anticancer agent. Preferably, it can show excellent effects against prostate cancer, breast cancer, lung cancer, colorectal cancer, pancreatic cancer, skin cancer, or uterine cancer.

[0021] WO 2015 / 178608 A2 discloses a 3,4-dihydroquinazoline derivative of the following chemical formula C, which induces cell cycle arrest in cancer cells by blocking the intracellular influx of calcium ions, a secondary signaling molecule essential for the proliferation and growth of cancer cells, thereby enhancing the efficacy of existing anticancer agents.

[0022] Chemical formula C:

[0023]

[0024] The compound described in the document exhibits cell cycle blocking activity in cancer cells and enhances the cytotoxicity of existing anticancer agents against cancer cells. A combination of the compound of the stated chemical formula C and other anticancer agents selected from the group consisting of antitumor platinum coordination complexes, anthracycline antibiotics, topoisomerase inhibitors, and tyrosine kinase inhibitors can be used to treat or prevent cancers such as lung cancer, sarcoma, malignant melanoma, pleural mesothelioma, bladder cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, breast cancer, colorectal cancer, kidney cancer, esophageal cancer, adrenal cancer, parotid gland cancer, head and neck cancer, cervical cancer, mesothelioma, leukemia, and lymphoma.

[0025] In confirming the efficacy of the compound of chemical formula 1 against various cancers, the inventors of this invention discovered that it exhibits particularly excellent cell viability (CVI) against breast cancer. 50After further research, the compound of chemical formula 1 of the present invention has a dual-target anti-cancer effect on triple-negative breast cancer cell lines MDA-MB-231, MDA-MB-453, Hs 578T, and BT20. That is, it has both the mechanism of blocking calcium overexpressed in cancer cells and essential for cancer cell growth and the mechanism of inhibiting signal transducer and activator of transcription 3 (STAT3) as a target protein. Thus, it has been confirmed that it can treat and prevent triple-negative breast cancer, thereby completing the present invention. Summary of the Invention

[0026] Technical issues

[0027] The purpose of this invention is to provide a pharmaceutical composition that can treat and prevent triple-negative breast cancer, a type of invasive breast cancer.

[0028] Furthermore, the purpose of this invention is to provide a compound of chemical formula 1 for medicinal use as a dual-target anticancer agent to treat and prevent triple-negative breast cancer.

[0029] Technical solution

[0030] In order to achieve the objectives described herein, the present invention provides a pharmaceutical composition for treating and preventing triple-negative breast cancer, comprising a compound of the following chemical formula 1.

[0031] Chemical Formula 1:

[0032]

[0033] The compounds of Formula 1 used in this invention are disclosed in WO 2014 / 021591 A2 and WO 2015 / 178608A2. The compounds of Formula 1 may exist in the form of pharmaceutically acceptable salts, hydrates, solvates, inclusion compounds, prodrugs and polymorphs.

[0034] To make the invention easier to understand, some terms are first defined.

[0035] As used in this invention, the term "pharmaceutical acceptable" means a nontoxic substance that does not substantially interfere with the biological activity of the compound of Formula 1.

[0036] As used in this invention, the term "prevention" refers to preventive treatment of a subject at risk of developing triple-negative breast cancer to reduce the probability of the pathological condition occurring in the subject, and the term "treatment" refers to both therapeutic treatment and preventive measures aimed at alleviating the disease or disorder (i.e., delaying or terminating or reducing at least one of the onset of the disease or its clinical symptoms) by reducing or alleviating at least one physical parameter, including parameters that the patient cannot identify.

[0037] The term "treatment or prevention" as used in this invention includes administering a compound of Formula 1 in combination with any one or more additional therapeutic agents to prevent or delay the onset of symptoms, complications, or biochemical signs of a disease (e.g., lung cancer, pancreatic cancer), thereby alleviating symptoms of the disease, pathological state, or disorder, or preventing or inhibiting the further development of the disease, pathological state, or disorder. Treatment can be preventive suppression of symptoms after the onset of a disease (aimed at preventing or delaying the onset of the disease, or preventing the expression of its clinical or subclinical symptoms) or therapeutic suppression or relief.

[0038] In this invention, "effective amount" refers to an amount sufficient to achieve a beneficial or desired result. For example, a therapeutic amount refers to an amount that achieves the desired therapeutic effect. This amount may be the same as or different from a preventive effective amount required to prevent the occurrence of disease or disease symptoms. An effective amount can be administered by more than one dose, topical application, or oral administration. The "therapeutic effective amount" (i.e., effective dosage) of a therapeutic compound varies depending on the selected therapeutic compound. The composition can be administered more than once daily to more than once weekly, for example, it may include lower frequencies of administration as described in this invention. Those skilled in the art will understand that factors, including but not limited to these, may affect the dosage and timing required for effective treatment of a subject: the severity of the disease or disorder, prior treatment, the subject's overall health and / or age, and any other pre-existing conditions. Furthermore, treatment of a subject with a therapeutically effective amount of a therapeutic compound as described in this invention may include a single treatment or a series of treatments. As used herein, the term "therapeutic effective amount" for compounds of this invention refers to an amount in which the compound of this invention induces a biological or medical response in a subject, such as relieving symptoms, alleviating pathological conditions, delaying or postponing disease progression, or preventing disease. In a non-limiting example, the term "therapeutic effective amount" means an effective amount that, when administered to a subject, at least partially alleviates, prevents, and / or reduces triple-negative breast cancer.

[0039] Without being limited by theory, the compound of chemical formula 1 used in this invention is 2-(3-(4-cyclohexylphenyl)-2-((3-(3,3-dimethylureido)propyl)(methyl)amino)-3,4-dihydroquinazolin-4-yl)-N-(4-fluorobenzyl)acetamide [2-(3-(4-Cyclohexylphenyl)-2-((3-(3,3-dimethylureido)propyl)(methyl)amino)-3,4-dihydroquinazolin-4-yl)-N-(4-fluorobenzyl)acetamide].

[0040] Furthermore, in various papers, the compound is described as 4-(4-fluorobenzylcarbamoylmethyl)-3-(4-cyclohexylphenyl)-2-[3-(N,N-dimethylureido)-N'-methylpropylamino]-3,4-dihydroquinazoline.

[0041] As used in this invention, the term "pharmaceutically acceptable salt" refers to a salt prepared from a non-toxic acid and base comprising pharmaceutically acceptable inorganic acids and bases, as well as organic acids and bases. Suitable pharmaceutically acceptable base addition salts of the compounds used in this invention include metal salts prepared from aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc, or organic salts prepared from lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine. Suitable non-toxic acids include, but are not limited to, acetic acid, alginic acid, anthranilic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethenesulfonic acid, formic acid, fumaric acid, furoic acid, galacturonic acid, gluconic acid, glucuronic acid, glutamic acid, glycolic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucoic acid, nitric acid, papoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, propionic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, and p-toluenesulfonic acid.

[0042] Unless otherwise indicated, the term "progrug" as used herein refers to a derivative of a compound that can be hydrolyzed, oxidized, or otherwise reacted under biological conditions (in vivo or in vitro) used to provide the compound. Examples of progrugs include, but are not limited to, biohydrolyzable components (moies) such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureas, and biohydrolyzable phosphate ester analogs. Progrugs can generally be prepared using well-known methods.

[0043] Unless otherwise used, the terms “biohydrolyzable amide,” “biohydrolyzable ester,” “biohydrolyzable carbamate,” “biohydrolyzable carbonate,” “biohydrolyzable urea,” and “biohydrolyzable phosphate” as used herein refer to amides, esters, carbamates, carbonates, ureas, or phosphates that are not affected by the biological activity of the compound but impart advantages such as uptake rate, duration of action, or signs of action to the compound in vivo; or 2) compounds that are biologically inert but can be converted into biologically active compounds in vivo. Examples of biohydrolyzable esters include, but are not limited to, lower alkyl esters, alkoxyalkyl esters, alkylamide alkyl esters, and choline esters. Examples of biohydrolyzable amides include, but are not limited to, lower alkylamides, α-amino acid amides, alkoxyacylamides, alkylaminoalkylcarbonylamides, and others. Examples of biohydrolyzable carbamates include, but are not limited to, smaller alkylamines, substituted ethylenediamines, amino acids, hydroxyalkylamines, heterocyclic amines, heteroaromatic amines, and polyetheramines.

[0044] Furthermore, the present invention provides a compound of chemical formula 1 for use as a dual-target anticancer agent in the treatment and prevention of triple-negative breast cancer.

[0045] According to the present invention, the target of administering the compound of chemical formula 1 is tumors of the triple-negative breast cancer cell lines MDA-MB-231, MDA-MB-453, Hs 578T, and BT20.

[0046] In the present invention, for the treatment or prevention of triple-negative breast cancer, the compound of Formula 1 may exist in the form of a pharmaceutically acceptable salt, hydrate, solvate, inclusion compound, prodrug, or polymorph isomer.

[0047] This invention confirms a method for treating or preventing triple-negative breast cancer by regulating T-type calcium channels and STAT3 activation, both in vitro and in vivo. Specifically, in the examples, it was confirmed that the compound of Formula 1 inhibits intracellular calcium influx through T-type calcium channels and regulates the activation of CaMKII protein in triple-negative breast cancer cell lines. Furthermore, another embodiment of the invention confirms that the compound of Formula 1 inhibits the formation of STAT3 dimers and regulates STAT3 phosphorylation by binding to the SH2 domain.

[0048] In another embodiment of the present invention, it was found that the compound of chemical formula 1 induces apoptosis through caspase activation by regulating the expression of regulatory proteins of the Bcl-2 family. The present invention exhibits an anti-cancer effect on triple-negative breast cancer by regulating the expression of regulatory proteins of the Bcl-2 family and thus through caspase activation-induced apoptosis mechanism.

[0049] In another embodiment of the invention, it was confirmed that the compound of Formula 1 inhibited tumor growth in a mouse model of induced triple-negative breast cancer and induced cell growth and apoptosis in tumor tissue obtained from the mouse model, thereby demonstrating its medicinal use with anti-cancer effects.

[0050] The present invention comprises a compound of chemical formula 1, which can be prepared into a pharmaceutical composition for single-dose administration for the prevention and treatment of triple-negative breast cancer.

[0051] To prepare a single-dose formulation comprising the pharmaceutical composition of the present invention and a compound of Formula 1, the compound of Formula 1 may be present in pharmaceutically acceptable salt, hydrate, solvate, inclusion compound, prodrug, or polymorphic isomer.

[0052] As described above, the compound of Formula 1, which is the active ingredient of the present invention, can be used to treat and prevent triple-negative breast cancer. The prophylactic or therapeutic dosage of the compound of Formula 1 of the present invention is varied. The dosage varies depending on age, weight, and individual patient response. A suitable dosing regimen can be appropriately selected by those skilled in the art. Generally, the recommended daily dosage range for the conditions described below is from about 0.01 mg / kg to 100 mg / kg. More specifically, the daily dosage is a uniformly distributed dose, administered 1 to 3 times per day. In some cases, as is known to those skilled in the art, it may be necessary to use dosages higher than those disclosed herein. Furthermore, clinicians or treatment practitioners need to understand how and when to intervene, adjust, and terminate the treatment based on the individual patient's response.

[0053] As used herein, “dosage” includes the dosage and frequency regimens described above. Other therapeutically effective amounts may be used for other diseases and conditions, as is known to those skilled in the art. Similarly, amounts sufficient to treat or prevent such disorders are those sufficient to alleviate but not to cause side effects associated with the compound of Formula 1, and are also included in the dosage and frequency regimens described above.

[0054] The single-dose administration of the present invention can be carried out by oral, mucosal (including rectal, nasal or vaginal), parenteral (subcutaneous, intramuscular, bolus, intra-arterial or intravenous), sublingual, or skin administration methods.

[0055] The pharmaceutical compositions and administration forms of the present invention comprise compounds of Formula 1 or pharmaceutically acceptable salts, hydrates, solvates, inclusion complexes, prodrugs, and polymorphs thereof, and typically contain pharmaceutically acceptable excipients.

[0056] The single-dose administration of the present invention can be delivered to the patient orally, via mucosal (e.g., nasal cavity, sublingual, vaginal, oral cavity, or rectum), parenteral (e.g., subcutaneous, intravenous, bolus, intramuscular, or intra-arterial), or transdermally.

[0057] Examples of dosage forms include tablets; Capsules; hard or soft capsules; cachets; tablets containing tablets; lozenges; sprays; suppositories; ointments; dressings; pastes; powders; dressings; creams; plasters; solutions; patches; aerosols (e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to patients, including solution dosage forms suitable for oral or mucosal administration (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or water-in-oil liquid emulsions), solutions, and elixirs; liquid dosage forms suitable for parenteral administration to patients; and sterile solid formulations.

[0058] The types of compositions, forms, and administration methods of the present invention vary depending on their intended use. For example, an administration method for short-term treatment of triple-negative breast cancer may contain more than one active ingredient than an administration method for long-term treatment of the same disease.

[0059] Similarly, the parenteral administration form may contain fewer than one active ingredient than the oral administration form used to treat triple-negative breast cancer. The specific administration forms included in this invention can be implemented in various ways according to embodiments practiced by those skilled in the art. For example, refer to Remington Pharmaceutical Sciences, 18th edition, Mack Publishing, Easton PA (1990).

[0060] The pharmaceutical compositions and administration methods of the present invention comprise one or more excipients. Suitable excipients are well known to those skilled in the pharmaceutical industry, and non-limiting examples of suitable excipients are described herein. Whether a particular excipient is suitable for inclusion in a pharmaceutical composition or administration method depends on various factors, such as the administration method to the patient.

[0061] For example, the oral delivery form of the present invention is prepared by combining the active ingredient with at least one excipient in a mixture using conventional pharmaceutical mixing techniques. Excipients can take various forms depending on the preparation form used for administration. For example, excipients suitable for oral liquid or aerosol administration include, but are not limited to, water, ethylene glycol, oils, alcohols, flavoring agents, preservatives, and coloring agents. Examples of excipients suitable for solid oral delivery forms (e.g., powders, tablets, capsules, and sac-like tablets) include, but are not limited to, starch, sugars, microcrystalline cellulose, diluents, granulators, lubricants, binders, and disintegrants. Tablets and capsules exhibit the most advantageous oral delivery forms for ease of administration. In this case, solid excipients are used. If necessary, tablets can be coated using standard aqueous or non-aqueous coating techniques. The above-described delivery forms can be prepared by any preparation method. Generally, the pharmaceutical compositions and delivery forms of the present invention are prepared by uniformly and tightly mixing a liquid carrier, a finely dispersed solid carrier, or both, with the active ingredient. Furthermore, if necessary, the product can be molded into the preferred form. For example, tablets can be prepared by compression or molding. Compressed tablets can be prepared by compressing an active ingredient in a free-flowing form, such as powder, granules, or powder, selectively mixed with excipients, in a suitable machine. Molded tablets can be prepared by molding a mixture of compounds as a moist powder having an inert liquid diluent in a suitable machine. The excipients that can be used in the oral administration forms of the present invention include binders, fillers, disintegrants, and lubricants. However, they are not limited thereto.

[0062] Binders suitable for use in the pharmaceutical compositions and administration of the present invention include corn starch, potato starch, natural or synthetic gums such as gelatin, gum arabic, alginate, tragacanth gum, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose), polyvinylpyrrolidone, methyl cellulose, pregelatinized starch, hydroxypropyl methyl cellulose, microcrystalline cellulose, and mixtures thereof. However, they are not limited thereto. Examples of fillers suitable for use in the pharmaceutical compositions and administration of the present invention include talc, calcium carbonate, microcrystalline cellulose, dextrin, kaolin, mannitol, silica, sorbitol, starch, and pregelatinized starch. However, they are not limited thereto. In the pharmaceutical compositions of the present invention, the binder or filler typically constitutes about 50% to 99% by weight of the pharmaceutical composition or administration form. Suitable forms of microcrystalline cellulose include, but are not limited to, AVICELEL-PH-101, AVICEL-PH-103, AVICEL RC-581, AVICEL-PH-105, and combinations thereof. The specific adhesive is a mixture of commercially available microcrystalline cellulose and sodium carboxymethyl cellulose, such as AVICELRC-581.

[0063] The effects of the invention

[0064] The compound of Formula 1 of this invention exhibits a dual-target anticancer effect against triple-negative breast cancer. Specifically, this invention demonstrates that by blocking T-type calcium channels in triple-negative breast cancer cells, it inhibits intracellular calcium influx, and by binding to the STAT3 SH2 domain, it inhibits the formation of STAT3 dimers and regulates phosphorylation, thereby suppressing excessive cancer cell growth and inducing apoptosis induced by caspase activation. Therefore, the compound of Formula 1 simultaneously possesses a mechanism for blocking calcium overexpressed in cancer cells and essential for cancer cell growth, as well as a mechanism for inhibiting STAT3 as a target protein.

[0065] Furthermore, this invention demonstrates that the compound of Formula 1 inhibits tumor growth in a xenograft mouse model of induced triple-negative breast cancer and exhibits antitumor activity through apoptosis in the tumor tissue of the mouse.

[0066] Therefore, the present invention provides a pharmaceutical composition for treating and preventing triple-negative breast cancer, comprising a compound of chemical formula 1. Attached Figure Description

[0067] Figure 1 The expression levels of T-type calcium channels and STAT3 targeted by the compound of Formula 1 of the present invention were confirmed by Western blot in breast cancer cell lines including triple-negative breast cancer.

[0068] Figure 2 This study illustrates the phosphorylation expression of CaMKII, an important kinase in calcium signaling, and changes in intracellular calcium influx caused by T-type calcium channel blockade induced by a compound of formula 1 in the MDA-MB-231 triple-negative breast cancer cell line. Part A shows the changes in CaMKII phosphorylation expression induced by the compound of formula 1 as confirmed by Western blot, while Part B shows the amount of calcium entering the cell from the extracellular space as confirmed by Fura-2am.

[0069] Figure 3 This section illustrates the effect of the compound of Formula 1 of the present invention on the formation of STAT3 dimers by binding to STAT3. Part A shows the formation of dimers by binding and reacting recombinant STAT3 protein with fluorescently labeled peptides. Part B shows the compound of Formula 1 of the present invention. Part C shows the control group S31-201. Part D shows the control group Static.

[0070] Figure 4 The diagram shows the phosphorylation of STAT3 induced in triple-negative breast cancer cell lines by treatment with the compound of Formula 1 of the present invention. Part A shows the results of treatment with 20 μM of the compound of Formula 1 for different times (30, 60, 120 minutes), Part B shows the results of treatment with different concentrations of the compound of Formula 1, and Part C is a confocal microscopy image of phosphorylated STAT3 expression in cells after treatment with 20 μM of the compound of Formula 1 for 1 hour.

[0071] Figure 5 This demonstrates the inhibitory effect of the compound of Formula 1 of the present invention on STAT3 hyperphosphorylation induced by IL-6 treatment in triple-negative breast cancer cell lines.

[0072] Figure 6 The diagram illustrates cell death induced in triple-negative breast cancer cell lines by the compound of Formula 1 of the present invention, as confirmed by TUNEL fluorescence staining. Part A shows cell death at different time points, and Part B shows cell death after treatment with different concentrations for 12 hours.

[0073] Figure 7 The effects of early and late apoptosis detection methods on cell death in triple-negative breast cancer cell lines induced by treatment with the compound of Formula 1 of the present invention were demonstrated.

[0074] Figure 8The diagram shows the increase in cleavage products of caspase-3, caspase-9, and PARP proteins induced by treatment with the compound of Formula 1 of the present invention in triple-negative breast cancer cell lines. Part A shows the cleavage products increasing over time, and Part B shows the cleavage products increasing with concentration.

[0075] Figure 9 The diagram illustrates the changes in Bcl-2 family protein expression induced by treatment with the compound of Formula 1 of the present invention in triple-negative breast cancer cell lines. Part A shows the changes over time, and Part B shows the changes with different concentrations (5, 10, 20 μM).

[0076] Figure 10 This paper illustrates the inhibitory effect of the compound of chemical formula 1 of the present invention on tumor growth in triple-negative breast cancer induced by the compound in a Xenogfraft mouse model using the triple-negative breast cancer cell line MDA-MB-231. Parts A and B show the tumor size at different concentrations, part C shows the tumor weight at different concentrations, and part D shows the changes in body weight at different concentrations.

[0077] Figure 11 This invention illustrates the expression and activation of p-STAT3, survivin, Bcl-2, and PARP-1 cleavage in tumors isolated from a xenograft mouse model inducing tumors with the compounds of Formula 1 of the present invention.

[0078] Figure 12 The expression of p-STAT3 and PCNA in tumor tissue induced by the compound of Formula 1 of the present invention in a xenograft mouse model using the triple-negative breast cancer cell line MDA-MB-231, as confirmed by immunohistochemistry, is shown. Detailed Implementation

[0079] The present invention will now be described in more detail through embodiments and experimental examples. These embodiments and experimental examples are used to illustrate the present invention more specifically, but the scope of the present invention is not limited to these embodiments and experimental examples.

[0080] Example 1: Screening and evaluation of various cancer cells

[0081] Cell viability assays were performed on 35 cell lines from six cancer types, including breast cancer. A culture medium was prepared in RPMI 1640 with 10% fetal bovine serum (FBS), 2 mM L-alanyl-L-glutamine, and 1 mM sodium pyruvate or a special medium. Cells were seeded in 384-well plates and cultured for 24 hours at 95% humidity, 5% CO2, and 37°C. Then, the cells were treated with the compound of formula 1 and cultured for another 72 hours. Finally, the cells were treated with a Cell Titer-GLO (Promega) detection reagent, and bioluminescence was measured using a PerkinElmer Evnision microplate reader to determine the concentration (IC50) of the compound that inhibited 50% cell viability. 50 The values ​​are shown in Table 1 below.

[0082] Table 1

[0083]

[0084] As shown in Table 1, cell viability (IC) was confirmed in 35 cell lines across 6 cancer types, including breast cancer. 50 The results confirmed that, compared with other cancer cell lines, the triple-negative breast cancer cell lines MDA-MB-231, MDA-MB-453, Hs 578T, and BT20 showed at least a 2-fold to a 7-fold difference in efficacy, demonstrating excellent cytotoxic effects.

[0085] Therefore, it can be seen that, compared with other types of cancer, the compound of chemical formula 1 of the present invention exhibits a special effect on triple-negative breast cancer.

[0086] Example 2: Evaluation of target expression in breast cancer cell lines

[0087] Eleven types of breast cancer cells, including triple-negative breast cancer cells (MDA-MB-231, MDA-MB-453, Hs 578T, BT20), were used in a 5x10⁻¹⁰ ratio. 5 Seed cells at a density of 100 mm in 100 mm culture dishes and culture for 2-3 days. Collect cells to a density of 1 x 10⁻⁶ cells / mL. 6Cells were divided into 100 cells and washed with PBS to remove media components. Cell lysis was performed using RIPA buffer, followed by centrifugation (4°C, 13000 rpm, 15 min), and the supernatant was transferred to a new tube. Protein quantification was performed using the Bradford Assay, and the sample was then boiled at 100°C to prepare a loading sample for Western blot analysis. The sample was loaded onto an 8% SDS-polyacrylamide gel and electrophoresed at 80V, then the voltage was increased to 100–120V (when transferring the loaded sample from the stacking gel to the running gel) for electrophoresis. After electrophoresis, the polyacrylamide gel was transferred to the membrane (the transfer buffer was diluted with 10X transfer buffer:methanol:DW at a ratio of 1:2:7 and incubated at 280 mA for 2 hours under ice conditions). The membrane was blocked with 5% skim milk for 30 minutes and washed with PBS-T (phosphate-buffered saline with Tween 20). The primary antibody was diluted in 5% BSA + NaN3 solution and reacted with the membrane for at least 12 hours. The membrane was then washed with PBS-T and reacted with 5% skim milk + secondary antibody for 1 hour and 30 minutes. The membrane was washed with PBS-T, then reacted with ECL solution. Bands were detected using imaging equipment to confirm the expression of T-type calcium channels (Cav), STAT3, and p-STAT3 proteins. The relative expression levels are shown in Table 2. Figure 1 middle.

[0088] As shown in Table 2 below and Figure 1As shown, in the MDA-MB-231, MDA-MB-453, Hs 578T, and BT20 cell lines, the expression levels of the T-type calcium channels and STAT3 targets targeted by the compound of Chemical Formula 1 of this invention are relatively high. Furthermore, in the case of MDA-MB-231, high expression of p-STAT3 (the activated form of STAT3) is also observed.

[0089] Surprisingly, no expression of T-type calcium channels (Cav), STAT3, or p-STAT3 proteins was detected in the breast cancer cell lines T47D, AU565, MDA-MB-415, EFM-19, ZR-75-1, CAMA-1, and MCF7.

[0090] Therefore, it can be seen that the compound of chemical formula 1 of the present invention has a specific effect on triple-negative breast cancer cell lines.

[0091] Table 2

[0092]

[0093] Based on the results of Examples 1 and 2, and taking into account the expression level of the target, subsequent studies were conducted using the MDA-MB-231 cell line to confirm the anticancer effect and mechanism of the compound of Chemical Formula 1 of the present invention against triple-negative breast cancer.

[0094] Example 3: Confirmation of the effect on intracellular calcium signaling by blocking T-type calcium channels

[0095] In this embodiment, in order to confirm the effect of the compound of chemical formula 1 of the present invention blocking T-type calcium channels, the expression level of calcium-calmodulin dependent protein kinase 2 (CaMKII), one of the important kinases belonging to the calcium signaling pathway, and the intracellular calcium concentration were evaluated.

[0096] Triple-negative breast cancer (MDA-MB-231) cells were used at a rate of 2 x 10⁻⁶. 6Cells were seeded at a concentration of 100 mm in 100 mm culture dishes and cultured for at least 12 hours. After removing the culture medium, the cells were treated with a 20 μM solution of compound formula 1 for different durations (3 hours, 6 hours, and 12 hours). Cells were then harvested, lysed using RIPA buffer, and centrifuged (4°C, 13000 rpm, 15 min). The supernatant was transferred to new tubes. Protein quantification was performed using the Bradford Assay, and the samples were then boiled at 95°C to prepare for loading and Western blot analysis. The sample was loaded into an 8% SDS polyacrylamide gel and electrophoresed at 80V. The electrophoresis was then performed at 100–120V (when the loaded sample was transferred from the stacking gel to the running gel). After electrophoresis, the polyacrylamide gel was transferred to a membrane (the transfer buffer was diluted with 10X transfer buffer:methanol:DW = 1:2:7 and incubated at 280mA for 2 hours under ice conditions), blocked with 5% skim milk for 30 minutes, and washed with PBS-T (phosphate-buffered saline with Tween 20) buffer. The primary antibody was diluted in 5% BSA + NaN3 solution and reacted with the membrane for at least 12 hours. After washing with PBS-T, the membrane was reacted with 5% skim milk + secondary antibody for 1 hour and 30 minutes. After washing with PBS-T, the membrane was reacted with ECL solution, and the bands were detected using imaging equipment to confirm the expression of the T-type calcium channel protein Cav and the changes in calcium-induced phosphorylation of CaMKII.Furthermore, triple-negative breast cancer cell lines were treated with the compound of Formula 1, then stained with fura-2 am, and the amount of calcium in the cells was measured. The cells were then treated with 2 μM thiapsigargin to block the amount of calcium flowing in from the cellular ER, and then 2 mM of calcium was injected from outside the cells. The amount of calcium moving from outside the cells to inside the cells was measured using a PTI calcium analyzer, as shown below. Figure 2 Part A and Part B.

[0097] like Figure 2 As shown, when triple-negative breast cancer (MDA-MB-231) cell lines were treated with the compound of Formula 1 of the present invention at a concentration of 20 μM for different time periods (3 hours, 6 hours, 12 hours), the expression of T-type calcium channels did not change. When treated with the compound of Formula 1 for more than 3 hours, the phosphorylation level of CaMKII decreased, and the amount of calcium entering the cell from the extracellular space decreased.

[0098] Therefore, it is known from the present invention that the compound of chemical formula 1 reduces intracellular calcium levels by blocking T-type calcium channels and regulates the activation of CaMKII protein, thereby exhibiting an effect on triple-negative breast cancer.

[0099] Example 4: Confirmation of the inhibition rate of target protein STAT3 dimer formation

[0100] STAT3 is a transcription factor that, upon receiving an upstream signal, undergoes phosphorylation to form a dimer, which then migrates into the cell nucleus, thereby regulating the expression of various genes. This embodiment aims to confirm the inhibition rate of the compound of Formula 1 of this invention on STAT3 dimer formation using the FP assay (fluorescence polarization).

[0101] Fluorescence polarization assay (FP assay) is a method for measuring the polarization value emitted by fluorescently labeled small molecules during excitation / emission. High molecular weight substances formed after binding with proteins have high polarization values, while low molecular weight substances have low polarization values.

[0102] Recombinant STAT3 protein was added to an assay buffer (10 mM HEPEs (N-2-hydroxyethylpiperazine-N'-(2-ethanesulfonic acid)) pH 7.5 buffer, with 50 mM sodium chloride, 1 mM EDTA, 2 mM dithiothreitol (DTT), and 0.01% Trioton X100 added). The protein was treated with different concentrations (0.01–100 μM) of the compound of Formula 1 of this invention, reacting at room temperature for 1 hour. Then, the protein was treated with a fluorescently labeled peptide (10 nM) bound to the recombinant STAT3 protein and reacted for 30 minutes. The polarization value (millipolrization, mP) was measured using a FP Fluorescein Dual module to determine the dimer formation inhibition rate, which is shown below. Figure 3 In parts A, B, C, and D of the present invention. As comparative compounds of the chemical formula 1 of the present invention, two STAT3 inhibitory compounds, S31-201 and Static, are used.

[0103] like Figure 3 As shown, by comparing and analyzing the mP values ​​of GST-STAT3 protein and peptide, it can be confirmed that the binding of GST-STAT3 protein to both proteins leads to an increase in the mP value. Figure 3 Part A), when treated with different concentrations (0.01–100 μM) of the compound of Formula 1 of the present invention, IC 50 The concentration was 14.2 ± 2.6 μM, which inhibited the binding of GST-STAT3 to peptides ( Figure 3 Part B), when reacted with S31-201 as a control group at different concentrations (0.01–1000 μM), IC50... 50 The value was 493.1 ± 32.8 μM, inhibiting binding ( Figure 3 Part C), when reacted with Static at different concentrations (0.01–1000 μM), IC50 50 The value was 739±18.6 uM, inhibiting binding ( Figure 3 (Part D).

[0104] Therefore, it is known from the present invention that the compound of chemical formula 1 inhibits the formation of STAT3 dimer, thereby showing an effect on triple-negative breast cancer.

[0105] Example 5: Confirmation of activation inhibition of the target protein STAT3

[0106] STAT3 is a protein (transcription factor) that promotes the expression of multiple genes involved in cancer cell growth, proliferation, metastasis, and drug resistance, thereby inhibiting apoptosis. Although several studies have shown that inhibiting STAT3 may produce strong anti-cancer effects, research on the development of STAT3-targeted anticancer agents worldwide is still insufficient.

[0107] This embodiment aims to confirm whether the compound of chemical formula 1 of the present invention can regulate the activation of STAT3, a target protein associated with the growth of triple-negative breast cancer cell lines.

[0108] Triple-negative breast cancer (MDA-MB-231) cells were used at a rate of 2 x 10⁻⁶. 6Cells were seeded in 100 mm culture dishes and cultured for at least 12 hours. After removing the culture medium, the cells were treated with a compound of formula 1 under the following conditions: at a concentration of 20 μM for different times (30, 60, 120 minutes) or at different concentrations (5, 10, 20 μM) for 24 hours. Cells were then harvested, lysed using RIPA buffer, and centrifuged (4°C, 13000 rpm, 15 min). The supernatant was transferred to new test tubes. Protein quantification was performed using the Bradford Assay, and the samples were boiled at 95°C to prepare for loading and Western blot analysis. The sample was loaded into an 8% SDS polyacrylamide gel and electrophoresed at 80V. The voltage was then increased to 100–120V (when transferring the loaded sample from the stacking gel to the running gel) for further electrophoresis. After electrophoresis, the polyacrylamide gel was transferred to a membrane (using transfer buffer diluted at a ratio of 10X:methanol:DW = 1:2:7, and incubated at 280mA for 2 hours under ice-cold conditions). The membrane was blocked with 5% skim milk for 30 minutes and washed with PBS-T (phosphate-buffered saline with Tween 20) buffer. The primary antibody was diluted in 5% BSA + NaN3 solution and reacted with the membrane for at least 12 hours. After washing with PBS-T, the membrane was reacted with 5% skim milk + secondary antibody for 1 hour and 30 minutes. After washing with PBS-T, the membrane was reacted with ECL solution, and bands were detected using imaging equipment to show the expression of STAT3 phosphorylation (tyrosin 705 residue). Figure 4In Parts A and B, triple-negative breast cancer cell lines were treated with a compound of Formula 1 at a concentration of 20 μM for 1 hour. The expression of phosphorylated STAT3 within the cells was then confirmed by confocal microscopy and illustrated. Figure 4 In part C.

[0109] like Figure 4 As shown, after treating triple-negative breast cancer (MDA-MB-231) with a 20 μM compound of the present invention for 30 minutes, no phosphorylation of STAT3 was observed. Figure 4 (Part A) After treatment with different concentrations of the compound of Formula 1 of the present invention for 24 hours, the phosphorylation of STAT3 was significantly reduced when treated with 20 μM of the compound of Formula 1. Figure 4 Part B), after treatment with the compound of formula 1 for 1 hour, intracellular phosphorylation of STAT3 was confirmed by intracellular imaging, and its expression was significantly reduced ( Figure 4 Part C).

[0110] Furthermore, it has been reported that the IL-6 cytokine can activate signal transduction via STAT3. Therefore, the expression of phosphorylated STAT3 can be used to confirm the increase of IL-6-induced STAT3 and the regulation of STAT3 phosphorylation by the compound of formula 1. Thus, triple-negative breast cancer cell lines were treated with different concentrations (5, 10, 20 μM) of the compound of formula 1, followed by treatment with IL-6 at a concentration of 10 ng / ml for 30 minutes. STAT3 phosphorylation was then confirmed by Western blot and illustrated. Figure 5 middle.

[0111] like Figure 5 As shown, the compound of Formula 1 of the present invention inhibits the increase in IL-6-induced STAT3 phosphorylation in a concentration-dependent manner. When treated with the compound of Formula 1 of the present invention, the abnormal activation of these STAT3 is reduced by inhibiting the phosphorylation of STAT3.

[0112] Therefore, according to the present invention, when triple-negative breast cancer cells that depend on STAT3 activity for growth are treated with the compound of Formula 1, cell growth is inhibited by inhibiting the STAT3 signaling mechanism.

[0113] As described above, the present invention, through Examples 4 and 5, confirms that the compound of Formula 1 inhibits STAT3 activation, i.e. phosphorylation, in triple-negative breast cancer cells. STAT3 forms a dimer by phosphorylation and functions as a transcription factor. The compound of Formula 1 inhibits phosphorylation by binding to the SH2 domain, thereby reducing the activation level of STAT3, which can prevent and treat triple-negative breast cancer.

[0114] Example 6: Evaluation of Apoptosis in Triple-Negative Breast Cancer Cell Lines

[0115] 1) Apoptosis was confirmed by TUNEL fluorescence staining.

[0116] This experiment was used to confirm apoptosis in triple-negative breast cancer cells. Cell death was confirmed under a microscope by using DAPI fluorescence staining (a method for observing the morphological characteristics of cell death, namely DNA condensation) and TUNEL fluorescence staining (a method for observing DNA fragmentation). Cells showing signs of death were identified by green fluorescence, while the staining of the cell nucleus was observed using blue fluorescence. This confirmed the cell death of MDA-MB-231 cells.

[0117] In this experiment, DAPI fluorescence staining and TUNEL assay were performed to confirm apoptosis in triple-negative breast cancer cells. Cells treated with the compound of Formula 1 of this invention at different concentrations (5, 10, 20 μM) for 12 hours or at a concentration of 20 μM for different times (3 hours, 6 hours, 12 hours) were fixed with 4% formaldehyde solution for 10 minutes. Following the manufacturer's instructions (in situ cell death detection kit, POD, Roche, Germany), the cells were stained with a mixture of terminal doxsynucleotidyl transferase dUTP nick end labeling (TUNEL), and then washed three times with PBS buffer. Furthermore, cells were stained with 4',6-diamidino-2-phenylindole (DAPI) and reacted for 10 minutes, then treated with mounting medium, and cell death was confirmed by fluorescence microscopy. The results are shown separately on [the images are not included in the provided text]. Figure 6 Part A and Part B.

[0118] like Figure 6 As shown, the green fluorescence of the breast cancer cell line (MDA-MB-231) treated with a 20 μM concentration of the compound of Formula 1 of the present invention increased over time. In particular, when treated with a 20 μM concentration for more than 6 hours, more than 50% of the cells underwent apoptosis, exhibiting significant cell death. Figure 6 Part A of the invention shows that the higher the concentration of the compound of Formula 1, the greater the increase in green fluorescence in the breast cancer cell line (MDA-MB-231), especially when treated at a concentration of 20 μM for more than 12 hours, significant cell death is observed. Figure 6 Part B).

[0119] 2) Identify apoptotic cells by comparing early and late apoptosis.

[0120] This experiment aims to identify apoptotic cells using early and late apoptosis assays.

[0121] The assay for early and late apoptosis utilizes the Annexin V / Propidium Iodium (PI) double staining assay. Annexin V is a calcium-dependent protein that readily binds to phosphoserine. Early apoptosis is characterized by the exposure of phosphoserine residues on the cytoplasmic side of the cell membrane to the outer side, which bind to Annexin V and produce green fluorescence. In late apoptosis, due to cell membrane damage, the binding of phosphoserine residues on the cytoplasmic side of the cell membrane to Annexin V increases. This cell membrane damage also leads to increased PI staining. Flow cytometry can be used to differentiate cell death based on the degree of Annexin V / PI staining.

[0122] MDA-MB-231 triple-negative breast cancer cell lines were treated with different concentrations (5, 10, 20 μM) of the compound of Formula 1 of this invention for 12 hours, then washed with PBS, mixed with Annexin V binding buffer (10 mM HEPES buffer with added sodium hydroxide (NaOH), 140 mM sodium chloride (NaCl), and 2.5 mM calcium chloride (CaCl2), pH 7.4), Annexin V and PI were added, and the mixture was reacted at room temperature in the dark for 30 minutes. The cells were then analyzed by flow cytometry within 1 hour and the results are shown below. Figure 7 middle.

[0123] exist Figure 7 In contrast to the control group, when the breast cancer cell line (MDA-MB-231) was treated with a compound of chemical formula 1 of the present invention at a concentration of 5 μM, apoptosis occurred, confirming a significant increase in apoptosis with increasing concentration.

[0124] Therefore, the compound of chemical formula 1 of the present invention increases the cytotoxicity of breast cancer cells and induces cell death through apoptosis, thereby preventing and treating triple-negative breast cancer.

[0125] Example 7: Caspase signaling mechanism in apoptosis of triple-negative breast cancer cells

[0126] To elucidate the signal transduction mechanism by which the compound of Formula 1 of this invention induces apoptosis, Western blot was used to confirm whether the caspase-dependent pathway, a major signal transduction mechanism for cell death, was activated, specifically the cleavage of caspase-3, caspase-9, and PARP proteins. Triple-negative breast cancer (MDA-MB-231) cells were cultured at 2 x 10⁻⁶ cells / year. 6Cells of a certain number were seeded in 100 mm culture dishes and cultured for at least 12 hours. After removing the culture medium, the cells were treated with a compound of formula 1 under the following conditions: at a concentration of 10 μM for different times (3, 6, 12 hours) or at different concentrations (5, 10, 20 μM) for 12 hours. Cells were then harvested, lysed using RIPA buffer, and centrifuged (4°C, 13000 rpm, 15 min). The supernatant was transferred to a new test tube. Protein quantification was performed using the Bradford Assay, and the sample was then boiled at 95°C to prepare it for loading and Western blot analysis. The sample was loaded into an 8% SDS polyacrylamide gel and electrophoresed at 80V. The voltage was then increased to 100–120V (when transferring the loaded sample from the stacking gel to the running gel) for further electrophoresis. After electrophoresis, the polyacrylamide gel was transferred to a membrane (using transfer buffer diluted at a ratio of 10X:methanol:DW = 1:2:7, and incubated at 280mA for 2 hours under ice-cold conditions). The membrane was blocked with 5% skim milk for 30 minutes and washed with PBS-T (phosphate-buffered saline with Tween 20) buffer. The primary antibody was diluted in 5% BSA + NaN3 solution and reacted with the membrane for at least 12 hours. After washing with PBS-T, the membrane was reacted with 5% skim milk + secondary antibody for 1 hour and 30 minutes. After washing with PBS-T, the membrane was reacted with ECL solution. Bands were detected using imaging equipment to confirm the cleavage expression of caspase-3, caspase-9, and PARP proteins, and the results were displayed separately. Figure 8Part A and Part B.

[0127] like Figure 8 As shown, when the MDA-MB-231 cell line was treated with 20 μM of the compound of Formula 1 of the present invention, the cleavage of PARP-1 increased after 3 hours of treatment, the activation of caspase 9 increased significantly after 6 hours of treatment, and the activation of caspase 3 increased significantly after 12 hours of treatment. Figure 8 (Part A), and, when the MDA-MB-231 cell line was treated with different concentrations of the compound of Formula 1 of the present invention, cleavage of PARP-1, caspase 9, and caspase 3 was observed at a concentration of 10 μM. Figure 8 Part B).

[0128] Therefore, according to the present invention, the compound of chemical formula 1 induces apoptosis through the caspase activation pathway, thereby preventing and treating triple-negative breast cancer.

[0129] Example 8: Mitochondria-dependent Bcl family protein mechanism

[0130] This experiment aims to confirm the mechanism by which the compound of Formula 1 of the present invention induces mitochondrial-dependent Bcl family protein activating in triple-negative breast cancer cell lines.

[0131] By utilizing a caspase-dependent apoptosis signaling mechanism, we identified the protein expression of the Bcl-2 family (Bcl-2, Bax, Bak) that regulates mitochondrial membrane translocation via an intrinsic pathway in triple-negative breast cancer cell lines, thus confirming the signaling mechanism of apoptosis. Triple-negative breast cancer (MDA-MB-231) cells were cultured at 2 x 10⁻⁶ ppm. 6Cells of a certain number were seeded in 100 mm culture dishes and cultured for at least 12 hours. After removing the culture medium, the cells were treated with a compound of formula 1 under the following conditions: at a concentration of 20 μM for different times (3 hours, 6 hours, 12 hours) and at different concentrations (5, 10, 20 μM) for 24 hours. Cells were then harvested, lysed using RIPA buffer, and centrifuged (4°C, 13000 rpm, 15 min). The supernatant was transferred to new test tubes. Protein quantification was performed using the Coomassie Brilliant Blue assay (Bradford Assay). The samples were then boiled at 95°C to prepare for loading and Western blot analysis. The sample was loaded into an 8% SDS polyacrylamide gel and electrophoresed at 80V. The electrophoresis was then performed at 100–120V (when the loaded sample was transferred from the stacking gel to the running gel). After electrophoresis, the polyacrylamide gel was transferred to a membrane (the transfer buffer was diluted with 10X transfer buffer:methanol:DW = 1:2:7 and incubated at 280mA for 2 hours under ice conditions), blocked with 5% skim milk for 30 minutes, and washed with PBS-T (phosphate-buffered saline with Tween 20) buffer. The primary antibody was diluted in 5% BSA + NaN3 solution and reacted with the membrane for at least 12 hours. After washing with PBS-T, the membrane was reacted with 5% skim milk + secondary antibody for 1 hour and 30 minutes. After washing with PBS-T, the membrane was reacted with ECL solution, and bands were detected using imaging equipment to confirm changes in the protein expression of the Bcl-2 family (Bcl-2, Bax, Bak), and the results are shown separately. Figure 9 Part A and Part B.

[0132] like Figure 9 As shown, Bcl-2 protein expression decreased with increasing treatment time with 20 μM of the compound of Formula 1 of the present invention on triple-negative breast cancer cells (MDA-MB-231), while Bax / Bak expression increased after 12 hours of treatment with the compound of Formula 1. Figure 9 (Part A) As the concentration of compound of formula 1 increases, the expression of Bcl-2 protein decreases, and the expression of Bax / Bak increases. Figure 9 Part B).

[0133] Therefore, according to the present invention, the compound of chemical formula 1 can regulate the expression of Bcl-2 family proteins, reduce the expression of Bcl-2 which inhibits apoptosis, and increase the expression of Bax which promotes apoptosis, that is, increase the expression of Bax relative to Bcl-2, thereby inducing apoptosis in breast cancer cells, and thus can prevent and treat triple-negative breast cancer.

[0134] Example 9: Inhibiting tumor growth in a xenograft mouse model

[0135] To confirm the anticancer effect of the compound of Chemical Formula 1 of the present invention on triple-negative breast cancer, the anticancer effect on triple-negative breast cancer cells was confirmed in an animal model.

[0136] The triple-negative breast cancer cell line MDA-MB-231 was used at 1.5 x 10⁻⁶. 7 Cells per mouse were subcutaneously injected into aged BALB / c / nu / nu nude mice to transplant the cell line and induce tumor formation, thereby establishing a tumor-inducing animal model (MDA-MB-231 derived xenograft mouse model). After 12 days, mice were divided into five groups: a drug administration group (15 mg / kg, 30 mg / kg, 60 mg / kg, oral administration 5 times / week for 66 days) of the compound of chemical formula 1 of this invention, a control group, and a paclitaxel administration control group (10 mg / kg intraperitoneally twice / week for 66 days). From the start of administration of the test substance to the date of dissection, body weight and tumor size were measured twice weekly. Tumor size was measured using calipers along the long and short axes, and calculated using the following formula (tumor size = ab² / 2 (a: long axis length, b: short axis length)). The results are shown below. Figure 10 Parts A, B, C, and D.

[0137] like Figure 10As shown in Parts A, B, and C, it can be confirmed that when the compound of Formula 1 of the present invention is administered to tumors derived from the MDA-MB-231 cell line, the tumor size in the control group significantly increased after 40 days. In contrast, tumor growth was delayed in the groups treated with the compound of Formula 1 of the present invention and with paclitaxel. In particular, it is known that when a low concentration of the compound of Formula 1 of the present invention (15 mg / kg) is administered, tumor growth is delayed by approximately 50% compared to the control group. At a concentration of 30 mg / kg, the same results as with paclitaxel, which has been conventionally used as an anticancer agent, are obtained, and at a concentration of 60 mg / kg, tumor growth is inhibited.

[0138] Moreover, such as Figure 10 As shown in section D, the compound of chemical formula 1 of the present invention was confirmed to inhibit tumor growth without causing changes such as weight loss in mice.

[0139] Therefore, the compound of chemical formula 1 of the present invention can not only inhibit tumor growth by inducing apoptosis in triple-negative breast cancer tumor tissue, but also delay tumor tissue growth without weight change.

[0140] Example 10: Tumor growth inhibition mechanism in a xenograft mouse model

[0141] To confirm the tumor growth inhibition mechanism of the compound of Formula 1 of this invention on triple-negative breast cancer cell lines, tumor tissue was obtained from xenograft mice induced from the triple-negative breast cancer cell line MDA-MB-231. Lysis buffer (20 mM Tris-HCl pH 7.4, 1% Trion X-100, 1 mM DTT, 1 mM EDTA, 1 mM EGTA, 1 mM PMSf, 150 mM NaCl) was added, followed by centrifugation (4°C, 15000 rpm, 10 min), and the supernatant was transferred to a new test tube. Protein quantification was performed using the Bradford Assay, and the sample was then boiled at 95°C to prepare for loading and Western blot analysis. The sample was loaded into an 8% SDS-polyacrylamide gel and electrophoresed at 80V. The voltage was then increased to 100–120V (when transferring the loaded sample from the stacking gel to the running gel) for further electrophoresis. After electrophoresis, the polyacrylamide gel was transferred to a membrane (using transfer buffer diluted at a ratio of 10X:methanol:DW = 1:2:7, and incubated at 280mA for 2 hours under ice-cold conditions). The membrane was blocked with 5% skim milk for 30 minutes and washed with PBS-T (phosphate-buffered saline with Tween 20) buffer. The primary antibody was diluted in 5% BSA + NaN3 solution and reacted with the membrane for at least 12 hours. After washing with PBS-T, the membrane was reacted with 5% skim milk + secondary antibody for 1 hour and 30 minutes. After washing with PBS-T, the membrane was reacted with ECL solution, and the bands were detected using imaging equipment to confirm changes in the expression of p-STAT3, survivin, Bcl-2, and PARP-1 cleavage markers related to tumor formation and apoptosis.Furthermore, tumor tissue obtained from xenograft mice induced by the triple-negative breast cancer cell line MDA-MB-231 was fixed in 10% formalin, then prepared into paraffin blocks. These blocks were reacted with primary antibodies against p-STA3 and PCNA at 4°C for at least 12 hours, washed with phosphate-buffered saline (PBS), and reacted with secondary antibodies at room temperature for 2 hours, followed by washing with PBS. Staining with 3,3'-diaminobenzidine (DAB) was performed, and the staining was confirmed by optical microscopy. The results are shown below. Figure 11 and Figure 12 middle.

[0142] exist Figure 11 In tumor tissues obtained from xenograft mice induced by the triple-negative breast cancer cell line MDA-MB-231, results were obtained in identifying proteins related to cell growth and apoptosis. It was confirmed that when the compound of chemical formula 1 of the present invention was administered at concentrations of 15 mg / kg, 30 mg / kg, and 60 mg / kg, the phosphorylation of STAT3 was significantly reduced. When administered at concentrations of 30 mg / kg and 60 mg / kg, the expression of survivin and Bcl-2 was reduced, and the activation of PAPR-1, which is involved in apoptosis, was increased.

[0143] exist Figure 12 In this study, for the compound of Formula 1 of the present invention, the expression of the target protein was confirmed in paraffin blocks prepared from tumor tissue obtained from xenograft mice induced by the triple-negative breast cancer cell line MDA-MB-231. The expression of p-STAT3, which was highly expressed in the control group, was significantly reduced after treatment with the compound of Formula 1 of the present invention. When the expression of proliferating cell nuclear antigen (PCNA), an important marker in cell division and carcinogenesis, was confirmed, the expression in tissues treated with the compound of Formula 1 of the present invention was significantly reduced compared with the control group.

[0144] Therefore, it is understood that the compound of chemical formula 1 of the present invention inhibits the activation of p-STAT3 involved in tumor growth, and induces apoptosis in tumor tissues derived from triple-negative breast cancer via typical apoptosis mechanisms by inhibiting the activation of PARP, Bcl-2 and survivin, which are markers of apoptosis mechanisms.

[0145] Therefore, in this invention, the compound of Formula 1 inhibits intracellular calcium influx into triple-negative breast cancer cells through T-type calcium channels, inhibits STAT3 dimer formation and regulates phosphorylation through binding to the STAT3 SH2 domain, regulates the expression of typical mitochondrial-dependent Bcl-2 family regulatory proteins, kills cells via caspase-activated apoptosis, inhibits tumor growth in a mouse model of induced triple-negative breast cancer, and exerts anti-tumor activity in mouse tumor tissues through apoptosis. Therefore, it can be developed into an anticancer therapeutic agent for triple-negative breast cancer.

Claims

1. A pharmaceutical composition for treating and preventing triple-negative breast cancer, characterized in that, The active ingredient comprises a compound of Formula 1 or a pharmaceutically acceptable salt, hydrate, solvate, inclusion complex, prodrug, or polymorph isomer thereof, and comprises a pharmaceutically acceptable carrier: Chemical Formula 1: 。 2. The pharmaceutical composition of claim 1, wherein, The triple-negative breast cancer is a tumor of the MDA-MB-231, MDA-MB-453, Hs 578T, or BT20 cell line.

3. The pharmaceutical composition of claim 2, wherein, The triple-negative breast cancer mentioned is a tumor of the MDA-MB-231 cell line.

4. The pharmaceutical composition of claim 1, wherein, The pharmaceutical composition is formulated into parenteral, transdermal, topical, mucosal, nasal, oral, sublingual, or oral dosage forms.

5. The pharmaceutical composition of claim 4, wherein, The pharmaceutical composition is formulated into an oral dosage form.

6. The pharmaceutical composition of claim 5, wherein, The oral dosage form is in tablet or capsule form.

7. The pharmaceutical composition according to claim 1, characterized in that, The daily dosage of the pharmaceutical composition prepared into a compound of chemical formula 1 is from 0.01 mg / kg to 100 mg / kg.

8. A method for treating or preventing triple-negative breast cancer in a subject requiring treatment or prevention, characterized in that, The procedure includes administering a therapeutically effective amount of the compound of Formula 1 according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, inclusion complex, prodrug, or polymorph isomer thereof, to the subject.

9. The method for treating or preventing triple-negative breast cancer in a subject requiring treatment or prevention, as described in claim 8, is characterized in that... The subjects were triple-negative breast cancers with MDA-MB-231, MDA-MB-453, Hs 578T, or BT20 cell line tumors.

10. The method for treating or preventing triple-negative breast cancer in a subject requiring treatment or prevention, as described in claim 8, characterized in that... It exhibits dual-target anticancer effects against tumors in the triple-negative breast cancer cell lines MDA-MB-231, MDA-MB-453, Hs 578T, and BT20.

11. The method for treating or preventing triple-negative breast cancer in a subject requiring treatment or prevention, as described in claim 10, characterized in that, The dual targets simultaneously possess the mechanisms of blocking calcium, which is overexpressed in triple-negative breast cancer cells and is essential for cancer cell growth, and inhibiting STAT3, a target protein.

12. The method for treating or preventing triple-negative breast cancer in a subject requiring treatment or prevention, according to any one of claims 8 to 11, characterized in that, It also has the mechanism of regulating the expression of Bcl-2 family regulatory proteins, thereby inducing apoptosis through caspase activation.

Citation Information

Patent Citations

  • 3,4-dihydroquinazoline derivatives

    WO2008136631A1

  • Novel compound, method for preparing same and pharmaceutical composition comprising same

    WO2014021591A2

  • 3,4-dihydroquinazoline derivative and complex preparation containing same

    WO2015178608A2